Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk выглядит как компания с очень сильной операционной рентабельностью, но с заметным напряжением в оценке по части баланса и ликвидности. P/E на уровне 14.08 ниже медианы отрасли на 34%, что поддерживает идею относительной недооценки по прибыли, особенно на фоне высокой ROE 61.36%, ROA 20.35% и ROI 38.79%. При этом P/S 4.01 выше медианы на 32.3%, а P/B 9.06 — более чем в четыре раза выше отраслевого уровня, что говорит о дороговизне по балансовой базе и выручке. P/FCF около медианы выглядит нейтрально и не даёт сильного аргумента ни за, ни против переоценки. Динамика мультипликаторов в целом благоприятная: P/E и P/S снижались по мере роста качества, что частично улучшает профиль оценки, хотя P/B остаётся очень высоким. Маржинальность остаётся выдающейся: чистая маржа 33.14%, операционная 41.31% и gross margin 80.98% — все существенно выше отрасли, хотя gross margin немного снизилась относительно прошлых периодов. Выручка, операционная прибыль и чистая прибыль в целом держатся на высоком уровне, а TTM net income и operating income подтверждают устойчивую генерацию прибыли. С другой стороны, ликвидность слабая: quick ratio 0.57 и current ratio 0.80 заметно ниже отраслевых ориентиров, что повышает чувствительность к краткосрочным обязательствам. Долговая нагрузка также не идеальна: debt/equity 0.61 выше медианы, а long-term debt вырос по сравнению с прошлым годом, что добавляет осторожности к оценке. Дивидендная доходность 3.45% выглядит привлекательнее, чем в прошлые периоды, и поддерживает инвестиционный кейс для долгосрочного держателя. Рост активов и собственного капитала позитивен, но при этом liabilities остаются значительными, а cash on hand не выглядит избыточным. В сумме фундаментал сильный по качеству бизнеса и прибыльности, но оценка уже не выглядит настолько дешёвой, чтобы агрессивно повышать целевую цену. Для инвестора это скорее история качественного бизнеса с хорошей доходностью и умеренным апсайдом, чем кандидат на резкое переоценивание.

Novo Nordisk A/S

Сильная прибыльность и низкий P/E поддерживают кейс, но высокая оценка по P/B и слабая ликвидность ограничивают потенциал пересмотра вверх.

Key Points
Pfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort.
That workhorse, called berobenatide, is performing as well as the company’s been hoping.
It could prove very marketable despite Eli Lilly’s and Novo Nordisk’s commanding lead in this race.
Pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are still the two titans of the weight loss drug market, to be sure. Lilly sold $13.5 billion worth of GLP-1-based Zepbound last year, while Novo reported revenue of more than $30 billion (U.S.) from its anti-obesity drugs Wegovy and Ozempic, with its weight loss arm experiencing year-over-year sales growth of more than 26%.
As is so often the case, though, would-be competitors aren't simply letting market leaders have unfettered access to a market that Morgan Stanley now believes will grow to a stunning $150 billion per year by 2035.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Drugmaker Pfizer (NYSE: PFE) is throwing its hat into the ring as well, recently offering a developmental update that should concern Novo Nordisk, Eli Lilly, and the shareholders of this weight-loss drug duopoly. Let's see what this could mean for all three companies.
Less is more
It's called berobenatide. In many ways, it's like the aforementioned Wegovy and Zepbound, as it leverages the GLP-1 (glucagon-like peptide-1) receptor pathway to induce weight loss. And it's administered by subcutaneous injection.
There is one big way Pfizer's anti-obesity drug berobenatide -- also known as PF-08653944 -- differs from Wegovy, Ozempic, and Zepbound, though. That is, whereas Lilly's and Novo's treatments are injected weekly, Pfizer's GLP-1 receptor agonist requires only a monthly injection to achieve comparable weight-loss results.
That's what the developmental update, unveiled recently at the 86th Scientific Sessions of the American Diabetes Association, suggests, anyway. As the company's corresponding press release explains, the drug's phase 2b trials successfully "highlight the potential for monthly delivery in a patient-friendly presentation with a very low 0.5 mL injection volume that provides convenience and scalability advantages" for patients with or without type 2 diabetes. It's also about as well tolerated as alternatives.
There are some measurable trade-offs, of course. While this particular study showed a typical weight loss of 15.9% at the 32-week mark, patients might do slightly better with Novo Nordisk's or Eli Lilly's GLP-1 options as part of a clinically managed or carefully followed treatment regimen.
However, given that its average weight loss reflects a wide range of inputs that may or may not be affected by deviations from a dosing or diet regimen, some patients could conceivably achieve better personal results. Some observers also argue that berobenatide may produce better net weight loss in the long run simply because it's easier to stick to its corresponding weight-loss plan.
The trial's results also affirm the idea that this drug may be effective at maintaining a lower weight once a user's weight-loss goal has been met.
The rest of the story is even more compelling
It's an obvious win for Pfizer. But even a late-phase 2b win for a single drug in its R&D pipeline isn't exactly game-changing for the company. There's still phase 3 testing to be done, which is not only time-consuming, but puts previous-stage results to the test on a wider scale. Veteran investors know all too well that the FDA can often spot something it doesn't like late in a drug's development that it didn't notice before.
Just understand that this same anti-obesity treatment -- berobenatide -- isn't just in one single mid-stage trial right now. It's currently undergoing a handful of similar trials as a weight-loss drug and a type 2 diabetes treatment, some of which are phase 3 trials -- the final stage before seeking regulatory approval. The market's already familiar with this drug and its safety profile. The recent update of its efficacy as a once-monthly, low-dose injection simply bolsters the overall optimism surrounding this drug, ultimately acquired with Pfizer's 2025 acquisition of drugmaker Metsera.
In a similar vein, Pfizer's update on phase 2b testing of low monthly doses of berobenatide gives the company another chance to tout that it actually has 10 different trials of this drug in or entering phase 3 by the end of this year. Moreover, it's got more than 20 anti-obesity treatments currently in the works at various stages of development.
Connect the dots. Pfizer is positioning to compete with Lilly and Novo. And it will be able to do so, even if only a handful of these trials meet their phase 3 targets.
Much to think about, and far too much to simply ignore
Just keep your expectations in check. Multiple trials means multiple launches of the drug, each with a narrowly range of approved uses. Pfizer's obesity business will only build slowly and won't begin making major contributions to the top and bottom lines for at least a few years.
As CEO Albert Bourla commented in the company's recent Q1earnings conference call "Starting in 2029, we will enter a five-year period of high single-digit revenue CAGR," with much of its growth from that point on being driven by recent acquisitions like Matsera. The three years between now and then, however, are going to remain mostly unimpressive as the company continues to struggle with the sharp wind-down of its once-red-hot COVID-19 drug business.
The market has a funny way of predicting and reflecting those predictions in stock prices -- well in advance, though.
Whatever the case, even what's just moderately bullish for Pfizer is more bearish for Eli Lilly and Novo Nordisk. Pfizer is introducing competition to the weight-loss drug market, which is already seeing slowing growth. If nothing else, the eventual launch of berobenatide will further erode the already-waning pricing power of Wegovy, Ozempic, and Zepbound. And Pfizer isn't the only outfit working on an alternative anti-obesity drug either.
Given that Lilly and Novo shares have been priced at a premium largely on the potential of their weight-loss drugs, Pfizer's update is an important reminder that nothing lasts forever. Shareholders of either company will most definitely want to keep close tabs on the ongoing development of berobenatide. It's a brewing problem, to be sure.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $438,283!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,257,427!*
Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 12, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

(RTTNews) - Novartis (NVS) unveiled late-breaking Phase 3 RemIND trial data at the EAACI Congress, highlighting the potential of Rhapsido (remibrutinib) as the first targeted therapy for chronic inducible urticaria (CIndU).
The study met its primary endpoints across the three most common CIndU subtypes—symptomatic dermographism, cold urticaria, and cholinergic urticaria—with responses seen as early as week 2 and sustained improvements by week 12.
Chronic inducible urticaria (CIndU) affects an estimated 29 million people worldwide, with everyday triggers such as pressure, heat, or cold leading to itchy wheals. Current antihistamine treatments often provide incomplete relief, and no targeted therapies are approved today.
Rhapsido, a selective oral BTK inhibitor, works by blocking histamine release, a key driver of hives and swelling. In the RemIND trial, complete response rates at week 12 were 29.3% for symptomatic dermographism, 56.3% for cold urticaria, and 29.3% for cholinergic urticaria compared with 14-16% for placebo.
Novartis has submitted a supplemental NDA to the FDA for the symptomatic dermographism subtype and plans additional filings globally in 2026. Rhapsido is already approved for chronic spontaneous urticaria (CSU) in multiple regions, and the new data reinforce its potential to expand into CIndU, addressing a significant unmet need.
NVO has traded between $35.12 and $81.44 over the past year. The stock closed Thursday's trading at $43.96, up 2.69%. In pre-market the stock is at $43.58, down 0.89%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria

Key Points
Viking is developing candidates in the high-growth weight loss drug market.
The company’s lead candidate is involved in late-stage studies.
Viking Therapeutics (NASDAQ: VKTX) has seen its stock stumble in recent times -- for example, it's slipped over the past year. But over five years, shares of the biotech company have climbed more than 300%. This is amid excitement about the company's potential in a market that's on track to reach nearly $100 billion in just a few years. I'm talking about the weight loss drug market.
Viking hasn't yet commercialized a drug, but it has a promising candidate in late-stage trials, so it may be very close to the finish line in this valuable market. All of this means the biotech, which specializes in developing candidates for metabolic and endocrine disease, might generate revenue -- and at significant levels -- in just a few years.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Though investors haven't rushed into the stock in recent months, this could soon change. Viking has catalysts just ahead: The company expects to report data from a maintenance dosing study of its weight loss drug candidate in the third quarter, and it aims to launch a phase 3 trial for the oral version of its candidate in the fourth quarter.
Considering this, is Viking stock going to $100? Let's find out.
Blockbuster weight loss drugs
We'll start with some details about Viking's lead candidate, VK2735. This is an investigational dual GLP-1/GIP receptor agonist, much like the popular drugs sold by market leaders Eli Lilly and Novo Nordisk. These drugs act on hormonal pathways involved in digestion, and as a result, they help control appetite and blood sugar levels. The Lilly and Novo drugs have become blockbusters, and demand has been consistently high for these products -- this is thanks to their efficacy, safety, and ease of use.
Though these pharma giants dominate the space, as mentioned, it is a high-growth market, so there is room for others to enter. And even if a company such as Viking doesn't take leadership -- and I wouldn't expect it to unseat a massive pharma company like Lilly or Novo -- it still could bring in blockbuster revenue. That could be quite a huge step for a young biotech.
And Viking does offer its own twist, differentiating itself from current GLP-1 drugs. At the moment, Lilly offers a dual GLP-1/GIP drug in injectable format and a GLP-1 drug in oral format. Novo's obesity drugs are GLP-1s. (Dual GLP-1/GIP drugs interact with two hormonal pathways, while GLP-1s interact with only one hormonal pathway.)
Injectable and oral formulations
Viking is developing VK2735 in both injectable and oral formats. So, if approved, it would be the first dual GLP-1/GIP drug available in oral format -- and the first dual available in both injectable and oral formats. One big advantage of this is that patients can shift from one formulation to the other -- for example, starting with the oral treatment and then using the injectable for maintenance once they've reached their desired weight.
The phase 3 trial for Viking's injectable is ongoing, and as mentioned, the phase 3 study for the oral formulation is set to begin later this year. We also should see data from its maintenance dosing trial in the months to come. These events could represent catalysts for the stock, which has been known to react to news. When Viking initially announced phase 2 data for VK2735 a couple of years ago, the stock soared more than 100% in one trading session.
So now, let's return to our question: Is Viking heading to $100? It reached a high of more than $94 when it announced phase 2 data in February of 2024. The stock has since given back much of that gain, and it trades today for about $27. But the average Wall Street estimate calls for it to reach more than $92 within the coming 12 months, recovering much of that territory.
The path to $100 represents a jump of more than 200%. I don't see that happening overnight like Viking's massive gain in February of 2024. But a few updates or general good news in the obesity drug market could help it along the way -- so Viking could indeed be heading to $100 in the quarters to come.
Should you buy stock in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 12, 2026.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is Viking Therapeutics Stock Going to $100?

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. Theglobal marketfor anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Eli Lilly Hovers Around $1 Trillion Valuation
Eli Lilly LLY shares hit a $1 trillion market value, closing at its first record high since November. The stock has surged more than 25% since the March 30 market low and gained over 400% in the past five years, making Eli Lilly one of Wall Street’s biggest beneficiaries of the obesity-drug boom, per Yahoo Finance. Shares surged about 14% over the past one month (as of June 4, 2026).
Reta Fuels Investor Optimism
Much of the recent excitement centers on retatrutide, or “Reta,” Eli Lilly’s experimental next-generation obesity treatment.
Unlike approved drugs such as Zepbound and Mounjaro, which target two hormone pathways, Reta targets three pathways tied to appetite control, blood sugar regulation and energy use.
In the Phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of participants lost at least 30% of their body weight, results often associated with bariatric surgery, per the same Yahoo Finance article.
GLP-1 Market Expands Beyond Obesity
Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment.
Alongside Eli Lilly, Novo Nordisk NVO, Amgen AMGN and Viking Therapeutics VKTX remain key players in the obesity-drug race. Meanwhile, Indian pharma major Lupin bets big on India’s GLP-1 market.
The trend is also affecting industries outside healthcare, including packaged food, alcohol, restaurant and retail stocks, as investors assess how appetite-suppressing drugs may reshape consumer behavior.
Deloitte Warns of a GLP-1 “Bubble”
A new report from Deloitte suggests soaring demand for obesity and diabetes drugs may be creating a “bubble effect” within the pharmaceutical industry, as quoted on CNBC.
Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage pipeline sales, surpassing oncology for the first time in 16 years.
According to Deloitte, GLP-1 and obesity drugs now represent about 38% of projected commercial inflows from the 2025 late-stage pipeline. Excluding these drugs, the industry’s R&D return falls sharply to 2.9%.
The report also highlighted concentration risk, noting that only 9% of blockbuster late-stage therapies is expected to generate nearly 70% of total risk-adjusted peak sales.
AI and Health Tech Join the GLP-1 Boom
The obesity-drug trend is also driving growth in health technology. Health-tech startup Signos recently raised $20 million in funding and expanded its partnership with Dexcom, per a CNBC article.
Signos uses AI-powered glucose monitoring technology alongside Dexcom’s continuous glucose monitors to help users manage weight through personalized recommendations tied to food, sleep, stress and lifestyle habits.
ETFs to Play
Roundhill GLP-1 and Weight Loss ETF OZEM, Tema Heart & Health ETF HRTS and Amplify Weight Loss Drug & Treatment ETF THNR are some of the ETFs that should be closely tracked in light of the above-mentioned scenario.
LLY-heavy ETFs like the iShares U.S. Pharmaceuticals ETF IHE, Harbor Health Care ETF MEDI and VanEck Pharmaceutical ETF PPH should also benefit from this trend.
NVO-heavy ETFs such as the Simplify Health Care ETF PINK and PPH are also in focus. Meanwhile, Amgen-heavy ETFs like the VanEck Biotech ETF BBH and iShares Biotechnology ETF IBB should not be overlooked amid this euphoria.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares Biotechnology ETF (IBB): ETF Research Reports
iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Amgen AMGN is one of the several drug makers racing to develop an innovative weight-loss drug and take a share of the booming weight loss drug market. The global obesity drug market is projected to grow dramatically, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates.
Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing. This key feature differentiates it from Eli Lilly’s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound (tirzepatide) and Wegovy (semaglutide), respectively, which are weekly injections. A monthly therapy like MariTide may help reduce treatment burden for patients and improve persistence on treatment over time.
Amgen is evaluating MariTide in type II diabetes, obesity and obesity-related conditions as part of its comprehensive MARITIME phase III program. Amgen has nine global phase III studies underway with MariTide in obesity and other obesity-related conditions like obstructive sleep apnea, cardiovascular disease and heart failure. Three phase III studies of MariTide in type II diabetes will be initiated in 2026.
In clinical studies, it has shown predictable and sustained weight loss and a clinically meaningful impact on cardiometabolic parameters.
In phase II studies, MariTide resulted in up to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau in people who were obese or overweight but without type II diabetes. In patients with type II diabetes who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks.
An interesting study is a new phase III switch study that will assess patients transitioning from weekly tirzepatide or semaglutide therapy to MariTide administered once every eight weeks or once every 12 weeks. In other words, the study will evaluate switching from Zepbound and Wegovy injections given 52 times a year to a medicine that can be injected 4 or 6 times a year.
MariTide is by far Amgen's most important obesity asset. However, Amgen’s obesity pipeline also includes earlier-stage oral and injectable candidates like AMG 513 and AMG 786.
Can AMGN Take Share from LLY and NVO in the Obesity Space?
MariTide is a closely watched drug in the obesity market. However, with MariTide, Amgen is entering a market that is heavily dominated by Lilly and Novo Nordisk. LLY and NVO already have a massive first-mover advantage in the obesity space and enjoy strong brand recognition.
Moreover, to maintain their prowess in the lucrative obesity market, both Novo Nordisk and Lilly are developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates.
Lilly's next-generation candidate, retatrutide, has demonstrated approximately 28% weight loss in late-stage studies, significantly above MariTide's approximately 20%.
This will make it difficult for Amgen to capture rapid market share on a weight-loss efficacy basis, even with a differentiated product like MariTide. However, from another perspective, the obesity market is huge and can support multiple players, and even a modest market share could translate into billions of dollars in annual revenues. MariTide’s less frequent dosing is its biggest competitive advantage, and if successfully developed and launched, MariTide could become the preferred option for patients who value convenience and durable weight maintenance.
Competition Heating Up in the Obesity Space
While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics and Viking Therapeutics are also developing oral GLP-1 drugs for treating obesity.
Others, such as Roche, Merck, AbbVie, and, more recently, Pfizer PFE, have strengthened their obesity pipelines through licensing deals and acquisitions involving smaller biotechs. Pfizer has strengthened its obesity presence with last year’s licensing of YP05002 from YaoPharma and the acquisition of Metsera. AbbVie entered the obesity field by licensing GUB014295 from Gubra. Roche strengthened its obesity presence through the acquisition of Carmot Therapeutics and its obesity assets, such as CT-388, as well as the exclusive collaboration with Zealand Pharma.
AMGN’s Price Performance, Valuation and Estimates
Amgen’s stock has risen 5.3% so far this year compared with an increase of 4.0% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.05 forward earnings, which is lower than 17.59 for the industry. The stock is also trading above its five-year mean of 13.81.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has declined from $22.29 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.43 to $23.70 per share over the same timeframe.
Image Source: Zacks Investment Research
Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Amneal Pharmaceuticals AMRX is building a growth narrative that leans less on any single product and more on scale across complex medicines. The company’s first-quarter results reinforced that setup, with earnings and revenue coming in ahead of expectations.
Management is investing in capacity for higher-value products while keeping a diversified base across generics, specialty brands, and government distribution.
AMRX Collaboration Shifts the Story to Scale
Amneal has a manufacturing and supply partnership for glucagon-like peptide-1 therapies with Metsera, which is now owned by Pfizer. The arrangement leverages Amneal’s peptide and sterile injectables infrastructure to support production of Pfizer’s glucagon-like peptide-1 and related metabolic therapies.
Strategically, it matters because it reinforces a pivot toward higher-value complex injectables and peptide therapeutics. It also helps frame Amneal less as a traditional generics story and more as a platform that can scale manufacturing in fast-growing categories.
Amneal’s GLP-1 Work Adds Revenue Without Discovery Risk
The core investor takeaway is the risk profile. The partnership offers revenue exposure tied to the rapid growth in metabolic therapies without Amneal bearing the clinical development costs and failure risk that come with discovering new drugs.
That difference is critical in a market dominated by innovators like Novo Nordisk NVO and Eli Lilly LLY, where clinical outcomes, labeling, and payer access can make or break returns. For Amneal, the economics are linked to manufacturing execution and capacity, not trial readouts.
AMRX Peptides and Sterile Injectables Become Core
Amneal is explicitly using the collaboration to deepen its capabilities in peptides and sterile injectables. The company describes this infrastructure as “growing,” and the Pfizer-linked work is positioned as a catalyst that strengthens manufacturing capability while building credibility in complex production.
Over time, that can improve positioning across other complex injectable opportunities as well. The logic is straightforward: capacity built for demanding metabolic therapies can support a broader portfolio, widening Amneal’s addressable opportunity set in higher-value dosage forms.
Amneal’s Kashiv Deal Could Deepen Biosimilars
In April 2026, Amneal signed a definitive agreement to acquire Kashiv BioSciences for up to $1.10 billion. The structure includes $375 million in cash and $375 million in equity, plus up to $350 million in milestone-based payments tied to regulatory and commercial achievements.
The transaction is expected to close in the second half of 2026, subject to customary closing conditions. The stated goal is to position Amneal as a fully integrated global biosimilar platform.
That ambition matters because biosimilars are not just another product category. They require deep development expertise, manufacturing rigor, and commercialization coordination. Established biosimilar specialists like Sandoz Group AG highlight how scale and repetition can become an advantage once the platform is built.
AMNEAL PHARMACEUTICALS, INC. Price and Consensus
AMRX Biosimilars and Complex Launch Cadence Matter
Amneal’s growth algorithm depends on cadence. The company expects Affordable Medicines to accelerate, with segment net revenues projected to grow 7% to 8% in 2026, supported by 20 to 30 new product launches each year, including complex products.
Biosimilars are part of that momentum. A biosimilar version of Novartis’ Xolair is under review, and approval would bring Amneal to six biosimilars in the United States.
At the same time, recent regulatory traction underscores the direction of travel in differentiated forms. The FDA approved Amneal’s romidepsin injection solution in a ready-to-use vial format, which management highlighted as more convenient than a powder requiring mixing. The product is also eligible for Competitive Generic Therapy designation, providing 180 days of market exclusivity.
Amneal’s Offsets Investors Can’t Ignore in 2026
The nearer-term headwind is Specialty. Management expects Specialty revenue growth to be roughly flat in 2026 as Crexont growth offsets anticipated generic erosion of Rytary, which has already seen an authorized generic and is expected to face additional generic entrants.
Pressure can also come from the base business. U.S. generics remain intensely competitive, and pricing pressure can squeeze margins even when volumes are healthy.
Finally, execution and timing risk remains real in complex products. Complex injectables, biosimilars, and niche specialty therapies face strict manufacturing requirements and rigorous regulatory scrutiny, and delays or slower-than-expected uptake can disrupt timelines.
What to Watch Through the Second Half of 2026 for AMRX
One should track the progress of the Kashiv acquisition closing in the second half of 2026 and any updates tied to regulatory and commercialization milestones that shape the total consideration.
Also, focus on execution in complex injectables, where differentiated formats and exclusivity windows can improve mix. The company is clearly pushing deeper into higher-value injectables, and the Pfizer-linked metabolic manufacturing work raises the bar for operational delivery.
Amneal’s 2026 outlook calls for net revenues of $3.05 billion to $3.15 billion and adjusted EBITDA of $740 million to $770 million, reflecting continued progress in profitability and cash generation as it invests for higher-value products.
AMRX’s Zacks Rank
Amneal currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Eli Lilly LLY stock continues to hit new all-time highs as the drugmaker keeps delivering a steady stream of positive clinical updates across its diabetes and obesity portfolio.
LLY shares reached a record high of $1,149.15 on Monday following encouraging clinical results from late-stage studies of Foundayo (orforglipron), its oral GLP-1 therapy, and retatrutide, its investigational triple-hormone receptor agonist that targets the GIP, GLP-1 and glucagon pathways. The latest data presented at the American Diabetes Association Scientific Sessions further reinforced confidence in the company’s cardiometabolic franchise.
Per data from the phase III ACHIEVE-3 head-to-head study, Foundayo outperformed Novo Nordisk’s NVO oral semaglutide across both blood sugar control and weight-loss measures in adults with type II diabetes (T2D). Patients receiving the highest Foundayo dose achieved greater A1C reductions and significantly higher weight loss than those taking oral semaglutide, while a larger proportion reached normal blood sugar levels.
Foundayo also produced strong results in two additional late-stage studies. In ACHIEVE-2, the drug delivered superior A1C reduction and weight loss compared with AstraZeneca’s Farxiga (dapagliflozin). In ACHIEVE-5, Foundayo significantly improved glycemic control and body weight when added to insulin therapy. Collectively, the data strengthen Lilly’s case for expanding Foundayo into the T2D market, with a regulatory filing planned by the end of the second quarter.
Lilly is also investing heavily in next-generation candidates to maintain continued future profitability. The company recently reported additional phase III results for retatrutide. In the TRIUMPH-1 study, patients receiving the highest dose lost an average of 28.3% of their body weight over 80 weeks, with nearly two-thirds no longer meeting the clinical definition of obesity. Beyond weight reduction, retatrutide demonstrated meaningful improvements in obesity-related conditions, including knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea. In the TRANSCEND-T2D-1 study, the candidate reduced A1C by up to 2% and delivered weight loss of up to 16.8%, with nearly half of the participants achieving normal blood sugar levels.
The latest findings build on positive top-line data Lilly had already reported from both the TRIUMPH-1 and TRANSCEND-T2D-1 studies earlier this year. Those earlier results established retatrutide’s ability to drive substantial weight loss and glycemic control. At the same time, the newly released detailed analyses further highlighted benefits across multiple obesity-related complications and cardiovascular risk factors. Together, the data continue to strengthen expectations that retatrutide could become one of Lilly’s most important future growth drivers.
Investors remain encouraged by Lilly’s ability to expand its leadership beyond blockbuster products like Mounjaro (T2D) and Zepbound (obesity), while simultaneously advancing next-generation therapies that could support long-term growth.
Lilly's Clinical Edge Continues to Pressure Novo Nordisk
Novo Nordisk remains Lilly’s fiercest rival in the obesity and diabetes markets. Novo Nordisk is also expanding its portfolio through higher-dose semaglutide products, label expansions and pipeline candidates such as CagriSema and amycretin.
However, Lilly’s recent string of clinical wins appears to be shifting competitive momentum in its favor. Foundayo’s superiority over Rybelsus in a direct phase III comparison and retatrutide’s impressive efficacy profile suggest Lilly could continue capturing market share across both diabetes and obesity. LLY now possesses a broad portfolio spanning injectable and oral therapies while also advancing next-generation treatments that may offer greater efficacy than currently available options.
LLY Faces Rising Pressure From Next-Generation GLP-1 Rivals
The obesity space has garnered much of the spotlight over the past year due to the sizeable and still underpenetrated market opportunity.
Smaller biotech firms, like Viking Therapeutics VKTX and Structure Therapeutics GPCR, are also advancing GLP-1–based therapies to challenge the incumbents. Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.
Structure Therapeutics’ phase II ACCESS study on its orally administered GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.
LLY’s Stock Price, Valuation and Estimates
Shares of Eli Lilly have gained 6.9% year to date compared with the industry’s 4.4% growth. During the same time frame, the company has also outperformed the sector but underperformed the S&P 500, as seen in the chart below.
LLY Stock Price Movement
Image Source: Zacks Investment Research
From a valuation standpoint, LLY stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 29.05 forward earnings, higher than 17.68 for the industry. However, the stock is trading below its five-year mean of 34.56.
LLY Stock Valuation
Image Source: Zacks Investment Research
Estimates for Eli Lilly’s 2026 earnings have improved from $35.47 to $35.67 per share in the past 30 days, and estimates for 2027 earnings have improved from $44.50 to $44.56 per share over the same time frame.
LLY Estimate Movement
Image Source: Zacks Investment Research
Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?

The global geopolitical landscape has plunged into a deep state of uncertainty once again following a direct exchange of missile strikes between Iran and Israel over the weekend. Although a fragile, temporary ceasefire was announced yesterday, history suggests there is no guarantee that hostilities will not resume at a moment’s notice in the Middle East.
This volatility may lead investors to rotate away from the highly volatile Silicon Valley investments, as they did last Friday. The sell-off was driven by a dual catalyst — a stronger-than-expected May U.S. jobs report, which reignited concerns that the Federal Reserve may keep interest rates higher for longer, and growing institutional anxiety over AI concentration risk and elevated valuations.
Such volatile situations tend to force risk-averse market participants to increase their positions in defensive safe havens like healthcare stocks and, by extension, healthcare exchange-traded funds (ETFs), which boast inelastic demand.
Before identifying those ETFs for your portfolio, a strategic investor must look past the immediate headlines. Examining the fundamental factors currently accelerating the healthcare sector, the primary players driving the sector’s rally, and assessing its future ensures that shielding your capital from global friction is an investment driven by hard data rather than reactionary panic.
Factors Fueling Healthcare & Major Players
The fundamental factors driving the healthcare sector’s recent expansion extend far beyond simple defensive positioning. The sector has been particularly flourishing of late due to two explosive factors: blockbuster weight-loss drugs and AI-driven drug discovery.
Leading the charge in the healthcare space is undoubtedly Eli Lilly LLY, which has defied broader market volatility to touch a new record 52-week high of $1,166 per share on June 5, 2026. Eli Lilly now controls roughly 60% of the booming GLP-1 weight-loss and diabetes market. It generated $13 billion in revenues in the first quarter of 2026, driven by LLY’s GLP-1 blockbuster drugs, Mounjaro and Zepbound, putting the company on an annualized run rate of more than $50 billion for its diabetes and weight-loss franchise. Meanwhile, recently released clinical trial data for its oral weight-loss drug, Foundayo, could further accelerate the franchise’s growth momentum.
The company is also rapidly scaling its AI drug discovery capabilities, heavily investing in advanced computing infrastructure and high-value partnerships to accelerate preclinical development. In January 2026, LLY joined forces with tech giant NVIDIA NVDA to co-invest up to $1 billion over five years in talent, infrastructure, and computing resources to support a new AI co-innovation lab aimed at accelerating and scaling drug discovery and manufacturing.
Similar to Eli Lily, Danish drugmaker Novo Nordisk NVO is another major player accelerating the growth of the healthcare sector. Alongside Eli Lily, NVO commands a lion’s share of the U.S. weight loss market and has been aggressively launching its weight-loss drugs across Europe, Asia and Latin America.
In December 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s oral obesity pill, Wegovy, making it the first GLP-1 tablet specifically cleared for chronic weight management. The company is also making its stride in AI-led drug discovery.
NVO entered into a strategic collaboration with OpenAI this April to integrate advanced AI capabilities across its value chain, from early-stage drug discovery to commercial operations. The partnership aims at accelerating the development and delivery of new therapies while enhancing operational efficiency through AI-driven insights and automation.
Outlook for Global Healthcare in the AI Era
In the era of AI, the global healthcare sector outlook is transformative. AI is no longer a Silicon Valley monopoly; it is slashing drug development timelines from years to months.
Agencies and healthcare groups are aggressively deploying agentic AI and multi-agent workflows to compress drug discovery timelines from years to months and automate clinical workflows. This structural evolution guarantees that healthcare is no longer just a slow-moving utility sector, but a hotbed of technological innovation.
To this end, a PWC report projects the global healthcare market to witness a 5% CAGR from 2025 to 2030, approaching nearly US$ 30 trillion, with the AI healthcare sub-industry estimated to reach $868 billion, yielding $222 billion in revenue gains.
Given this strong growth potential, geopolitical uncertainty stemming from the recurring tensions between Iran and Israel is likely to keep risk-averse investors on the defensive, prompting them to seek refuge in the healthcare sector's stable, recession-resilient cash flows.
Health ETFs to Buy
For those looking to capitalize on the healthcare sector’s growth momentum, as mentioned above, without facing the regulatory or clinical trial risks of individual stock picks, the following healthcare ETFs represent the best investment vehicles:
State Street Health Care Select Sector SPDR ETF XLV
This fund, with assets under management (AUM) worth $39.24 billion, offers exposure to 60 companies in the pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology industries. LLY holds the first spot in this fund, with 16.21% weightage.
Pharma giants, Johnson & Johnson JNJ holds the second position in this fund, with 10.15% weightage, while AbbVie ABBV holds the third spot with 7.26% weightage.
XLV has soared 12.5% over the past year. The fund charges 8 basis points (bps) as fees. It sports a Zacks ETF Rank #1 (Strong Buy) and traded at a good volume of 20.71 million shares in the last trading session.
Vanguard Health Care Index Fund ETF Shares VHT
With net assets of $16.6 billion, this fund provides exposure to 405 companies engaged in the manufacture of healthcare equipment and supplies, the provision of healthcare-related services, and the research, development, production, and marketing of pharmaceutical and biotechnology products. LLY is the fund’s largest holding, accounting for 12.13% of assets, followed by JNJ at 8.82% and ABBV at 6.03%.
VHT has rallied 13.3% over the past year. The fund charges 9 bps as fees. It sports a Zacks ETF Rank #1 and traded at a volume of 0.41 million shares in the last trading session.
iShares U.S. Pharmaceuticals ETF IHE
This fund, with net assets worth $921.5 million, offers exposure to 55 U.S. drug manufacturers and vaccine producers. LLY holds the first spot in this fund, with 24.52% weightage. JNJ holds the second position in this fund, with 20.75% weightage, while Royalty Pharma holds the third spot with 5.18% weightage.
IHE has surged 36.7% over the past year. The fund charges 38 bps as fees. It holds a Zacks ETF Rank #2 (Buy) and traded at a volume of 0.10 million shares in the last trading session.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike

Altimmune ALT is trying to ride a clear shift in liver drug development. Programs are increasingly designed to hit multiple pathways at once, rather than relying on a single lever like weight loss alone. For Altimmune that approach centers on pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist positioned as a “pipeline in a product” across several liver-related settings.
The next year matters because it puts this strategy into real-world execution. With pivotal planning in MASH and readouts approaching in alcohol-related conditions, 2026 will help determine whether multi-mechanism liver therapies can translate into durable, clinically meaningful outcomes.
ALT’s Thesis Fits a Shift Toward Multi-Pathway Therapies
Liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH) are not single-driver problems. They involve fat accumulation, inflammatory signaling, and progressive fibrosis. That biology has pushed drug development toward combinations and multi-mechanism assets, including dual and even triple agonist designs.
Pemvidutide is Altimmune’s entry into this shift. The company’s core claim is that balanced glucagon plus GLP-1 activity in one molecule can address liver biology directly while also improving metabolic factors that contribute to disease progression.
Altimmune, Inc. Price and Consensus
Altimmune’s Differentiation Claim vs GLP-1 Alone
Altimmune’s differentiation argument starts with the liver’s central role in glucagon signaling. In its framing, glucagon works directly on the liver and may help reduce liver fat, inflammation, and scarring. GLP-1, by contrast, is primarily tied to appetite reduction and weight loss, with potential anti-inflammatory benefits as well.
The point is not that GLP-1-driven weight loss is irrelevant. Instead, Altimmune is positioning glucagon activity as additive, aiming to push beyond weight loss alone and more directly influence hepatic fat and fibrosis-related pathways that matter for long-term disease modification.
ALT’s Data That Supports “Differentiated” Positioning
The company’s 48-week phase IIb MASH dataset is the backbone of that positioning. Pemvidutide showed statistically significant MASH resolution without worsening of fibrosis at 24 weeks, and the effect was sustained through 48 weeks.
More importantly for the “differentiated” narrative, multiple non-invasive markers associated with fibrosis and liver stiffness improved versus placebo, and the benefits deepened from 24 to 48 weeks, which Altimmune frames as evidence of sustained antifibrotic activity over time.
Safety and tolerability were also described as favorable, with low discontinuation rates and no serious treatment-related adverse events reported. The higher 1.8 mg dose group continued to lose weight through 48 weeks without plateauing, supporting a profile that could keep improving with longer treatment.
Altimmune’s 2026 Milestones as Trend Validation Points
The next major test is the planned global phase III registrational PERFORMA study in MASH patients with moderate-to-severe liver fibrosis. Altimmune expects to initiate the study in the second half of 2026, following alignment with the FDA on key parameters for late-stage development.
In parallel, pemvidutide is being evaluated in alcohol use disorder (AUD), with top-line phase II data from the RECLAIM study expected in the third quarter of 2026. Enrollment was completed in November 2025, ahead of schedule, which reduces one common source of timeline slippage.
If these milestones land cleanly, they would reinforce investor interest in dual-agonist liver programs that can credibly claim multi-pathway impact, not just metabolic improvements.
ALT’s Alcohol-Related Disease Expansion Could Broaden the Story
Altimmune is also building a second leg to the story in alcohol-related conditions. The company is running a phase II program in alcohol-associated liver disease (ALD) as well as the phase II AUD trial, framing both as areas of significant unmet need with commercial potential.
Operationally, the ALD RESTORE phase II study began in July 2025, and enrollment is expected to be completed by the third quarter of 2026. Together with the AUD readout, these programs support the “pipeline in a product” strategy by extending the same mechanism into adjacent, liver-relevant indications.
Altimmune’s Partnering Takeover Angle in a Crowded Field
The competitive landscape is crowded. In MASH, Altimmune is up against GLP-1 leaders such as Novo Nordisk NVO and Eli Lilly LLY, as well as a wide range of mechanisms and combination strategies from large pharma and MASH-focused players. NVO and LLY currently carry a Zacks Rank #3 (Hold).
Against that backdrop, the company is framed as an attractive licensing or takeover candidate if it keeps executing and the differentiated profile holds up in larger studies. The counterweight is concentration risk: Altimmune remains heavily dependent on pemvidutide, and a phase III failure in MASH would be a major blow.
ALT’s Key Watch Items for Trend Investors
For investors following the growing shift toward multi-pathway liver therapies, several key milestones will be important to watch. These include the timing of Phase III initiation and the outcome of FDA interactions as Altimmune finalizes the PERFORMA study design. Investors will also be focused on enrollment progress across ongoing trials, including the completion of ALD enrollment and the timely release of top-line data from the AUD study. Another area of attention is manufacturing preparedness, as Altimmune has already secured clinical supply and expects its production process to be scalable to support potential global Phase III needs. Finally, the competitive landscape remains an important consideration, particularly as rapidly advancing GLP-1 combination therapies and other novel mechanisms could narrow pemvidutide’s differentiation and increase the standard required to support best-in-class positioning.Bottom of Form
In a field where narrative advantage can disappear quickly, execution and durability of effect will decide whether ALT’s dual-agonist thesis becomes a template or just another crowded contender.
Altimmune’s Zacks Rank
ALT currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune ALT is building its investment case around a single clinical asset with multiple shots on goal in liver disease. Pemvidutide sits at the center of that thesis, with mid-stage data in metabolic dysfunction-associated steatohepatitis and active studies in alcohol-related conditions.
For investors, the story is simple: execution on the next wave of clinical milestones, paired with enough capital to reach them, can define the stock’s setup into 2026 and beyond.
ALT’s Liver Disease Focus and Why It Matters
Altimmune is a late clinical-stage biotechnology company focused on therapies for liver diseases. The company is incorporated in Delaware and headquartered in Gaithersburg, MD.
It has not generated product sales revenue to date. Operations have been funded through equity, debt and grants, leaving the business reliant on external capital while it advances clinical development.
That funding model matters because the value of the equity is closely tied to clinical progress, particularly progress tied to pemvidutide. With revenues still minimal and inconsistent, the stock can be sensitive to trial outcomes and timelines.
Altimmune’s Pemvidutide Is a “Pipeline in a Product”
Pemvidutide is Altimmune’s lead candidate and the company’s core value driver. It is being developed across three serious liver-related indications: metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Management has positioned pemvidutide as a “pipeline in a product” because the same molecule is intended to address multiple disease settings that share metabolic and hepatic injury pathways. The company has also indicated it may evaluate additional indications that leverage pemvidutide’s profile.
This concentration creates leverage both ways. A successful pivotal program in metabolic dysfunction-associated steatohepatitis can expand strategic options, including partnering interest, but the company is also heavily dependent on one drug.
Altimmune, Inc. Price and Consensus
ALT’s Dual Glucagon and GLP-1 Design in Plain English
Pemvidutide is designed as a balanced 1:1 dual agonist that activates both glucagon and glucagon-like peptide-1 receptors. Altimmune’s thesis is that combining these two pathways in a single molecule can improve liver and metabolic outcomes more broadly than a single-pathway approach.
In plain terms, glucagon activity is intended to work directly on the liver and may help reduce liver fat, inflammation, and scarring. The glucagon-like peptide-1 component is intended to support weight loss by reducing appetite, with potential anti-inflammatory benefits as well.
Altimmune believes that pairing these effects can address multiple aspects of liver disease at once, while also driving weight loss that can matter clinically for patients with metabolic dysfunction-associated steatohepatitis.
Altimmune’s EuPort Tech and Tolerability Angle
Pemvidutide uses Altimmune’s proprietary EuPort technology, which is designed to slow how the drug is absorbed. The company’s rationale is that slower absorption may improve tolerability.
Altimmune has highlighted the potential for reduced gastrointestinal side effects, a common challenge with therapies that act on glucagon-like peptide-1 biology. Better tolerability can support persistence on therapy, which can be important for longer-duration liver endpoints.
The company has also pointed to simple dosing as a potential adherence advantage versus more complex injectable regimens, which could matter if pemvidutide moves into larger, global trials.
ALT’s MASH Data Readout and the Phase III Path
In its phase IIb IMPACT study, pemvidutide achieved statistically significant metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, and the response was sustained through 48 weeks.
By 48 weeks, Altimmune reported signs consistent with antifibrotic activity, alongside continued improvement in markers tied to liver damage and inflammation, with the added benefit of weight loss.
Altimmune has stated it reached alignment with the Food and Drug Administration on key parameters for a late-stage study. The company expects to initiate the global phase III registrational PERFORMA study in the second half of 2026, with 52-week data anticipated in 2029.
Altimmune’s AUD and ALD Catalysts for 2026
Beyond metabolic dysfunction-associated steatohepatitis, pemvidutide is being evaluated in separate phase II programs in alcohol-related disease, which Altimmune views as significant unmet-need markets.
For alcohol use disorder, the RECLAIM phase II study completed enrollment in November 2025. Altimmune expects top-line data in the third quarter of 2026, setting up a clear catalyst window next year.
For alcohol-associated liver disease, the RESTORE phase II study began in July 2025, and enrollment is expected to be completed by the third quarter of 2026. Together, these readouts broaden the 2026 news flow beyond the metabolic dysfunction-associated steatohepatitis pivotal setup.
ALT’s Regulatory Tailwinds and What They Signal
The Food and Drug Administration granted Fast Track designation to pemvidutide for metabolic dysfunction-associated steatohepatitis and alcohol use disorder, and Breakthrough Therapy Designation for metabolic dysfunction-associated steatohepatitis.
These designations generally reflect the seriousness of the conditions and the unmet medical need, while also signaling that regulators see enough potential benefit to support development efficiency. They do not remove execution risk, but they can help keep timelines clearer as trials scale.
Competition remains intense, including large players such as Novo Nordisk NVO and Eli Lilly LLY, both currently carrying Zacks Rank #3 (Hold). For ALT, the near-term focus is whether pemvidutide’s multi-indication strategy translates into durable, registrational-quality outcomes across liver disease.
Altimmune’s Zacks Rank
ALT currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	14.08 21.32
Price/Sales	4.01 3.03
P/B	9.06 2.24
P/FCF	18.43 18.29

Indicator	TTM Median
ROE	61.36 24.59
ROA	20.35 6.73
ROI	38.79 10.20
Net Worth	187.78 0.21
Quick Ratio	0.57 1.75
Current Ratio	0.80 2.86

Indicator	TTM Median
Net Profit Margin	33.14 11.36
Operating Margin	41.31 14.26
Gross Margin	80.98 69.35
Return on tangible equity	188.71 51.50

Indicator	TTM Median
EPS	0.71 0.38
EPS Forecast	0.66 0.38
Revenue	12.34B 17.00M
Gross Profit	10.02B —
EBITDA	5.82B —

Novo Nordisk A/S

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue